In a follow‐up randomized, placebo controlled, phase 3 study (REACH‐2), restricted to AFP‐high (≥400 ng/ml) HCC patients, single agent ramucirumab led to a RECIST v1.1 objective response rate (ORR) of 5%, disease control rate of 59.9%, progression‐free survival of 2.8 months and overall survival of 8.5 months.6 This evidence concerns the gene AFP and hepatocellular carcinoma.